You are here: HomeNews → News Story

Richard Bruton, Minister for Jobs, Enterprise & Innovation, Prof Dermot Kenny & Ms. Julie Sinnamon CEO Designate, Enterprise Ireland



Prof. Dermot Kenny, BDI PI was shortlisted as a finalist in the inaugural Irish Clinical Innovation awards which recognise the importance of clinical innovation in Ireland. The focus of his application was the BDI development of a dynamic platelet function assay, with which Dermot and his team have demonstrated the potential to not only detect the effect/efficacy of anti-platelet therapies such as aspirin and Plavix but to also differentiate between patients with stable and acute coronary artery disease. The team has also been the first in the world, to analyse platelet function in neonates, an achievement made possible by the low blood volumes required for the test.

The awards hosted jointly by Enterprise Ireland and Cleveland Clinic, USA recognise the importance of clinical innovation in Ireland. The purpose of the award is to tap in to Ireland's clinical community with a view to developing new healthcare products and services that will improve patient care and benefit both the health care system and Ireland's medical technologies sector. Results were announced at the recent Med in Ireland conference, with REMPAD winning the overall prize. As a finalist, Dermot receives funding from Enterprise Ireland to pursue a feasibility study focused on the potential to partner with the Cleveland Clinic on the clinical and commercial development of his innovative technology.